Table 1: Clinical and biochemical characteristics of the patients according to treatment with gliclazide (Group 1) or KATP channel AB-site binding sulfonylureas (Group 2).

Entire group ( )Group 1 ( )Group 2 ( )

Sex (males/females)50/5129/2621/250.921
Age (years) 0.673
Diabetes duration (years) 0.839
Baseline BMI (kg/m2) 0.729
SU dose (% max dose) 0.160
Baseline HbA1c (%) 0.122
HbA1c after 6 months (%) 0.094
HbA1c (%) 0.717

BMI: body mass index; SU: sulfonylurea derivatives; values for difference between Group 1 and Group 2.